Compare · ELV vs FLGT
ELV vs FLGT
Side-by-side comparison of Elevance Health Inc. (ELV) and Fulgent Genetics Inc. (FLGT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELV and FLGT operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $86.50B, about 157.6x FLGT ($548.9M).
- ELV has more recent analyst coverage (23 ratings vs 9 for FLGT).
- Company
- Elevance Health Inc.
- Fulgent Genetics Inc.
- Price
- -
- -
- Market cap
- $86.50B
- $548.9M
- 1M return
- +5.43%
- -
- 1Y return
- +28.66%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- News (4w)
- 0
- 0
- Recent ratings
- 23
- 9
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Fulgent Genetics Inc.
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves insurance, hospitals, and medical institutions. It sells its tests through internal sales force, as well as through independent sales representatives in the United States and internationally. Fulgent Genetics has collaboration with PWNHealth to provide at-home COVID-19 test capabilities. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
Latest ELV
- Elevance Health Strengthens Connected Cancer Care Model to Support Consumers Through Their Health Journey
- Director Peru Ramiro G bought $366,050 worth of shares (1,000 units at $366.05), increasing direct ownership by 10% to 10,908 units (SEC Form 4)
- President and CEO Boudreaux Gail bought $1,002,230 worth of shares (2,725 units at $367.79), increasing direct ownership by 2% to 171,976 units (SEC Form 4)
- SEC Form 10-Q filed by Elevance Health Inc.
- Elevance Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance
- Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2026 Results on July 15, 2026
- New Elevance Health Public Policy Institute Study Examines Payment Disputes for Planned Procedures Under the No Surprises Act
- Thomas Carr Howe Middle School Unveils New Fitness and Strength Training Space Through Partnership with Elevance Health and Impact Fitness Foundation
- Elevance Health Makes Clinical Review Faster, More Connected with Health OS
Latest FLGT
- SEC Form 10-Q filed by Fulgent Genetics Inc.
- Fulgent Genetics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Fulgent Reports Second Quarter 2026 Financial Results
- CFO and Treasurer Kim Paul covered exercise/tax liability with 2,747 shares, decreasing direct ownership by 0.76% to 359,798 units (SEC Form 4) (withholding obligation)
- President and COO Xie Jian covered exercise/tax liability with 4,361 shares, decreasing direct ownership by 1% to 363,244 units (SEC Form 4) to satisfy tax liability
- Chief Scientific Officer Gao Hanlin covered exercise/tax liability with 1,645 shares, decreasing direct ownership by 0.17% to 988,729 units (SEC Form 4) to satisfy withholding obligation
- Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
- President and COO Xie Jian sold $38,382 worth of shares (2,146 units at $17.89), decreasing direct ownership by 0.58% to 367,605 units (SEC Form 4) (tax withholding)
- CFO and Treasurer Kim Paul covered exercise/tax liability with 2,087 shares, decreasing direct ownership by 0.57% to 362,545 units (SEC Form 4) to cover taxes
- Chief Scientific Officer Gao Hanlin sold $30,191 worth of shares (1,688 units at $17.89), decreasing direct ownership by 0.17% to 990,374 units (SEC Form 4) (withholding obligation)